Introduction: There is no approved second-line treatment for malignant pleural mesothelioma (MPM). On the basis of promising early results, pembrolizumab was used off-label in Switzerland and Australia. We investigated outcomes in association with clinicopathological features and expression of programmed death ligand 1 (PD-L1).
Results: A total of 93 patients (48 from Switzerland and 45 from Australia) were treated; 68 patients (73%) had epithelioid MPM, and 67 (72%) had an Eastern Cooperative Oncology Group performance status of 0 or 1. Pembrolizumab was the second-line treatment in 48 of 93 patients (52%). PD-L1 expression results were available for 66 patients (71%). Most (68%) were negative, 18% were intermediate, and 14% were high for PD-L1 expression. In the full cohort, the overall response rate (ORR) was 18%, the median progression-free survival (mPFS) was 3.1 months, and the median overall survival was 7.2 months. In patients with an Eastern Cooperative Oncology Group performance status of 0 or 1 and only one previous systemic treatment (n ¼ 35), the ORR was 37%, the mPFS was 3.7 months, and the median overall survival was 10. Conclusion: These real-world data demonstrate similar response rates but inferior survival compared with those in early-phase trials. High PD-L1 expression and nonepitheloid histological subtype were associated with greater activity. Anti-PD-L1 immunotherapy is a reasonable second-line therapy in patients with MPM.
Introduction
Malignant pleural mesothelioma (MPM) has a dismal prognosis, with a median overall survival (mOS) of 12 months. 1 After initial cisplatin/pemetrexed, there is no standard second-line therapy, and although gemcitabine or vinorelbine are often used, they have limited efficacy.
2,3
The signal-finding KEYNOTE-028 phase Ib trial of pembrolizumab demonstrated a disease control rate (DCR) of 72% and mOS of 18 months in 25 patients with progressive MPM and level of tumor programmed death ligand 1 (PD-L1) expression of 1% or more. 4 Largely on the basis of these results, pembrolizumab was used offlabel in Switzerland and Australia in the palliative setting. We collected data investigating the outcome of pembrolizumab treatment in MPM in a real-world setting, including exploratory analyses of histological subtypes and PD-L1 expression.
Materials and Methods
A total of 19 centers in Switzerland and Australia participated. The Australian and Swiss data were collected retrospectively and anonymized by predefined templates and an electronic case report form, respectively. The list of recorded parameters is provided in the Supplementary Methods. This retrospective analysis was approved by local ethics committees in both countries.
The Swiss samples were evaluated centrally for PD-L1 staining by a quality-approved university center (University Hospital of Basel, Switzerland). Membranous PD-L1 expression on tumor cells was quantified in archived formalin-fixed, paraffin-embedded samples by using the Ventana SP263 assay (Ventana Medical Systems, Tucson, AZ) according to the standard protocol. In Australia, formalin-fixed, paraffin-embedded tissue was analyzed with the immunohistochemistry (IHC) clone E1L3N (Cell Signaling Technology, Danvers, MA). Two experienced centers undertook PD-L1 staining (Olivia Newton-John Cancer Research Institute and Royal Prince Alfred Hospital), with samples read by two blinded investigators. PD-L1 expression was considered negative, intermediate, and high at tumor cell expression levels less than 5%, from 5% to 49%, and 50% or higher, respectively.
Statistical analyses were performed with R software (version 3.4.1, www.r-project.org) and stratified by country of origin. Censoring for survival occurred at the time at which the patient was last known to be alive or at last contact. Survival was assessed by using the KaplanMeier and Cox regression methods. p Values were two sided and not adjusted for multiple testing.
This work was funded by Grison Cancer League and Schweizerische Unfallversicherungsanstalt, Lucerne, Switzerland, and institutional academic funds in Australia.
Results
A total of 93 patients (48 from Switzerland and 45 from Australia) were treated between September 2015 and April 2017 with investigator-chosen doses of pembrolizumab varying from 200 mg every 21 days (used mostly) to 10 mg/kg body weight every 14 days, 2 mg/ kg body weight every 21 days, 2 mg/kg every 14 days, or 200 mg every 14 days (Table 1) .
Of the 93 patients, 66 (71%) had a performance status (PS) of 0 or 1; of these patients, 35 received pembrolizumab as either first-or second-line systemic treatment (38%). The median time from diagnosis to initiation of pembrolizumab treatment was 10.2 months for the entire cohort (range 0.6-114.3 months). Patient characteristics, histological subtype, and prior therapy are summarized in Table 1 .
In all, 66 patients (71%) had material available for PD-L1 quantification; 45 of 66 samples (68%) were PD-L1-negative, 12 of 66 (18%) were PD-L1-intermediate, and nine of 66 (14%) were PD-L1-high ( Supplementary Fig. 1 ).
At data cutoff (April 18, 2017), 18 patients (19%) were still undergoing treatment and in 75 (81%) pembrolizumab had been discontinued on account of disease progression, death, or toxicity. The median duration of treatment was 3.0 months (95% confidence interval [CI]: 2.7-4.1 months) and the median follow-up was 9 months (interquartile range 5-11 months) ( Supplementary Fig. 2 ).
In the full cohort, the overall response rate (ORR) was 18% (17 of 93) (one complete remission and 16 partial remission [ Table 2 ]). Disease control (complete remission, partial remission, and stable disease as best response) was achieved in 48% of patients (45 of 93). The median progression-free survival (mPFS) was 3.1 months (95% CI: 2.6-4.0) and the 6-month progression-free survival (PFS) rate was 26% (95% CI: 18%-37%). The mOS was 7.2 months (95% CI: 4.9-10.0), whereas 6-and 12-month OS times were reached by 58.5% (95% CI: 49%-70%) and 25% (15%-41%) of patients, respectively (Fig. 1) Table 2 and Fig. 1 Table 2 ).
PD-L1 expression was significantly associated with nonepithelioid histological subtype (p ¼ 0.001) (Fig. 3) . On univariate analysis, higher PD-L1 expression was associated with response (ORRs of 11%, 42%, and 44% [p ¼ 0.01] for negative, intermediate, and high expression, respectively) (see Table 2 Supplementary Fig. 3) . In a multivariate analysis, neither histological subtype nor PD-L1 expression remained significantly associated with outcome at any cutoff (Supplementary Data 2) .
Treatment was well tolerated. Only 25 treatmentrelated adverse events (18 being grade 1 or 2) were reported in 22 patients (24%; [ Supplementary Fig. 4 ]. In seven cases, pembrolizumab was discontinued on account of toxicity (grade 3; fatigue [in two patients], fever with cardiac decompensation, hepatotoxicity, nephrotic syndrome, arthralgia, and flare of polymyalgia rheumatica). There were no new safety signals.
Discussion
This is the largest retrospective analysis of outcomes in patients receiving pembrolizumab for advanced MPM outside of a clinical trial. In this unselected population we observed an ORR of 18%, with an mPFS of 3.1 months and mOS of 7.2 months. Enhanced activity was seen in patients with the nonepithelioid histological subtype and with PD-L1-positive tumors. Not surprisingly, earlier line of treatment and better PS were associated with better outcomes with pembrolizumab.
Patients with nonepithelioid MPM have a worse natural disease course than do those with the epithelioid histological subtype, and they are less responsive to chemotherapy. 5 The observation of an improved DCR and PFS in nonepithelioid MPM in our cohort, and in a recently presented phase II trial, 6 is of great importance, as it suggests that immunotherapy could improve outcomes for this chemoresistant subgroup. This may be due to the association between nonepithelioid histological subtype and higher PD-L1 expression, as there is often a more pronounced T-cell infiltrate in such tumors. 2, 7 Interestingly, nonepithelioid histological type was not associated with worse survival, suggesting that pembrolizumab may have negated this expected difference. Our data, for the first time, suggest a role for early immunotherapy in this group.
The role of PD-L1 expression as an immunotherapy biomarker remains controversial. 8 We have demonstrated a more favorable outcome in patients with a level of PD-L1 expression higher than 5%, which compares well with the available data (Supplementary Table 3 ). More importantly, in high expressers we found significantly higher ORR and mPFS and a numerically better mOS, although this subgroup represented only 14% of cases. Although PD-L1 expression may be associated with an exhausted T-cell phenotype and sensitivity to PD-1 inhibitors, an ORR of 11.1% was also seen in patients with low PD-L1 expression. However, in multivariate analysis PD-L1 was not independently predictive, so the exact clinical interpretation of PD-L1 expression remains complex and needs further elucidation.
Our unselected, real-world population performed worse than expected compared with patients in earlyphase trials. 4, 9 This outcome might be in part explained by the fact that only 71% of our cohort had a PS of 0 or 1 and would not meet the strict eligibility criteria of a phase 1/2 trial, such as adequate organ function and lack of adverse prognostic factors. Nevertheless, this cohort compares favorably with the widely used second-line chemotherapeutic options, suggesting that immunotherapy generally represents a valid option in this setting.
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